zzaatt, to say "it did not work out" is a huge understatement.
Many of us long term shareholders had followed the company's progress of its CLI therapy for several years. We endured numerous delays and other disappointments related to other projects. We hung in there because we were under the impression that the phase 3 results would be highly favorable. We finally thought our patience was about to be rewarded. Wednesday's PR was a gut punch. Not only did the Phase 3 trial fail, but the company announced that it was terminating the trial and shifting its resources to other indications. Just like that, forget about our CLI treatment.
Going forward, I believe PSTI will have a huge credibility problem. I can't envision any big financial institutions or funds wanting to invest much money in PSTI. Borrowing money may also be a problem.